• Research highlight
• Open Access

• Received: 5 June 2016
• Accepted: 6 June 2016
• Published: 21 July 2016

In the terminal stages of many chronic diseases, including cancer, loss of body mass may occur, which cannot be prevented or corrected by nutritional supplementation. This condition is termed cachexia, defined as >5% weight loss within 6 months. In addition to the loss of adipose tissue and overall metabolic imbalance, a typical characteristic of cachexia is muscle atrophy, resulting in fatigue and fetal weakness. Cancer cachexia is commonly observed in up to 80% of patients with advanced-stage disease and is one of the primary causes of cancer-related morbidity and mortality [1–3]. In fact, in cancer patients receiving radical therapy, cachexia can also occur. In patients with nasopharyngeal carcinoma from endemic areas, whose tumors are naturally sensitive to radiotherapy [4, 5], cachexia can be induced by radical radiotherapy in patients with post-irradiation nasopharyngeal necrosis [6]. Even worse, cachexia can usually induce resistance against conventional anti-cancer therapies, and no drug has been approved to treat or prevent cachexia in current medical practice [7].

It is believed that early diagnosis of and intervention in cancer cachexia can control its fetal progression, improve a patient’s quality of life, and prolong survival [8]. However, the underlying molecular mechanisms of cancer cachexia are largely unclear, preventing the development of effective intervention approaches. In a study recently published in Nature Medicine, entitled “Excessive fatty acid oxidation induces muscle atrophy in cancer cachexia,” Fukawa et al. [9] report their interesting findings that cachectic cancer cells secrete multiple inflammatory factors, including interleukin-6 and tumor necrosis factor-alpha, which have been suspected to play roles in cancer cachexia for decades [10, 11]. This secretion results in fatty acid oxidation and activation of a p38 stress-response signature in the skeletal muscles before presentation of cachectic muscle atrophy.

In this study, the authors also demonstrate that blockade of fatty acid oxidation using etomoxir can rescue human myotubes in vitro and can increase muscle mass and body weight in cancer cachexia animal models [9]. Therefore, targeting fatty acid-induced oxidative stress has a great potential for preventing cancer-induced cachexia.

The application of stable cachexia animal models is one of the strengths of this study. As shown in Fig. 1, the human clear cell renal cell carcinoma cell line RXF393 can stably induce cachexia in nude mice after several weeks of subcutaneous inoculation or orthotopic inoculation of the cancer cells into the subrenal capsule area.

Much more information can be found in the authors’ dataset from high-throughput expression profiling of human myotubes after exposure to cachectic or non-cachectic conditioned media [9]. The involvement of multiple cytokines reported in this comprehensive study also indicates that certain other causal factors may play a role in cancer cachexia, and especially those factors responsible for adipose tissue rearrangement.